Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Buys NGS Sample Prep Assets from IntegenX

NEW YORK (GenomeWeb News) — WaferGen Biosystems said today that it has acquired the next-generation sequencing library preparation business of IntegenX.

Under the agreement, WaferGen Inc., a subsidiary of WaferGen Biosystems, has acquired all of IntegenX's assets surrounding instruments and reagents related to NGS library preparation, including the Apollo 324 instrument and PrepX reagents.

The purchase price for the acquisition was composed of an up-front cash payment of $2 million; a $1.25 million secured promissory note due on Jan. 6, 2017; up to three earn-out payments based on certain revenue thresholds in 2014, 2015, and 2016; and WaferGen's assumption of certain liabilities related to the acquired business.

IntegenX's NGS library prep business is "highly synergistic with our existing products, especially our NGS target enrichment SmartChip TE offering," WaferGen President and CEO Ivan Trifunovich said in a statement.

Trifunovich added that the combined products "address a wide spectrum of customer needs in sample preparation for NGS and enable one-stop shopping for laboratories performing targeted sequencing."

Concurrent with the acquisition, and following its September 2013 fundraising, WaferGen has also shuffled and reduced the size of its board of directors. Upon closing of the acquisition, IntegenX CEO Robert Schueren joined WaferGen's board. In addition, WaferGen appointed William McKenzie, most recently vice president and general manager of molecular diagnostics at PerkinElmer, as a director.

Meantime, Scott Davidson, Joseph Pesce, Robert Coradini, and Timothy Triche have all recently stepped down from WaferGen's board.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.